12.12.23
Charles River Laboratories entered into an agreement with CELLphenomics, a service-based biotechnology company using 3D hydrogel technology to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. The enhanced offering will provide Charles River clients with access to CELLphenomics’ 3D tumor model platform to further optimize oncological approaches for its clients.
Leveraging CELLphenomics technology, Charles River will now have a novel in vitro option for identifying therapeutics for rare and ultra-rare disease types.
The agreement will also provide CELLphenomics access to Charles River’s genomically annotated and in vivo characterized cancer model database to develop PD3D models. The database is comprised of more than 700 tumor models, including PDX, cell lines and cell line-derived xenografts (CDX). These models have been extensively profiled for histological features, molecular data, and sensitivity to standard-of-care compounds, allowing a precise selection of suitable tumor models for preclinical anti-cancer agent testing.
“The field of 3D in vitro services for oncology research is rapidly developing,” said Aidan Synnott, corporate vice president, global discovery services, Charles River. “We’re excited for the integration of CELLphenomics’ tumor model platform into our existing portfolio of products and services.”
“This agreement allows us full access to Charles River’s impressive biobank and data,” said Christian Regenbrecht, CEO, CELLphenomics. “Now we can provide them with high quality models of the same genomic background through the entire preclinical development process – literally for any solid tumor type. From large high-throughput in vitro screens to selected PDX models, with Charles River as our partner, we can ensure an even more swiftly developmental process for novel anti-cancer drugs. Together, we make our customers’ compounds work.”
Leveraging CELLphenomics technology, Charles River will now have a novel in vitro option for identifying therapeutics for rare and ultra-rare disease types.
The agreement will also provide CELLphenomics access to Charles River’s genomically annotated and in vivo characterized cancer model database to develop PD3D models. The database is comprised of more than 700 tumor models, including PDX, cell lines and cell line-derived xenografts (CDX). These models have been extensively profiled for histological features, molecular data, and sensitivity to standard-of-care compounds, allowing a precise selection of suitable tumor models for preclinical anti-cancer agent testing.
“The field of 3D in vitro services for oncology research is rapidly developing,” said Aidan Synnott, corporate vice president, global discovery services, Charles River. “We’re excited for the integration of CELLphenomics’ tumor model platform into our existing portfolio of products and services.”
“This agreement allows us full access to Charles River’s impressive biobank and data,” said Christian Regenbrecht, CEO, CELLphenomics. “Now we can provide them with high quality models of the same genomic background through the entire preclinical development process – literally for any solid tumor type. From large high-throughput in vitro screens to selected PDX models, with Charles River as our partner, we can ensure an even more swiftly developmental process for novel anti-cancer drugs. Together, we make our customers’ compounds work.”